Document Detail


Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors.
MedLine Citation:
PMID:  23094948     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Objective. The correlation between plasma Chromogranin A concentrations and changes in tumor size evaluated by computed tomography (CT) - as a gold standard - was evaluated. Material and methods. One hundred and sixteen patients with CgA-producing ileo-cecal neuroendocrine tumors were evaluated by events, which were recorded when a CT was followed by another CT 1 - 12 months later. Change in tumor size was defined as regression, progression, or stable disease using RECIST criteria 1.1. Of 426 events, there were 97 with progression, 279 with stable disease, and 50 with regression. Based on the ROC curves a cutoff value of 25% change was selected to discriminate between increased, decreased, or unchanged CgA concentrations in plasma, using a sensitive radioimmunoassay with well-defined epitope specificity. Results. In the 97 events showing tumor progression diagnostic sensitivity and specificity of an increased CgA concentration were 86% and 86%, respectively. The positive and negative predictive values were 64% and 85%, respectively. In the 279 events with unchanged tumor size the diagnostic sensitivity and specificity of an unchanged CgA concentration were 73% and 86%, and the positive and negative predictive values were 91% and 63%, respectively. In the 50 events showing tumor regression, diagnostic sensitivity and specificity of a decrease in CgA concentration were 78% and 91%, the positive and negative predictive values being 55% and 97%. Conclusions. CgA concentrations in plasma have a high diagnostic accuracy in monitoring patients with ileo-cecal neuroendocrine tumors. In particular, an increase in plasma CgA concentration was useful to indicate tumor progression.
Authors:
Kenneth Højsgaard Jensen; Linda Hilsted; Claus Jensen; Tommie Mynster; Jens F Rehfeld; Ulrich Knigge
Related Documents :
24955518 - Brafv600e in papillary thyroid carcinoma is associated with increased programmed death ...
24947698 - Proactive infectious disease approach to dermatologic patients who are taking tumor nec...
21296388 - Clinical utility of fluorescence in situ hybridization for prediction of residual tumor...
7619718 - Childhood ganglioglioma and medically intractable epilepsy. a clinicopathological study...
3809398 - Energy metabolism and blood perfusion in a mouse mammary adenocarcinoma during growth a...
12007188 - Aberrant expression of cell-cycle regulator cyclin d1 in breast cancer is related to ch...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-24
Journal Detail:
Title:  Scandinavian journal of gastroenterology     Volume:  -     ISSN:  1502-7708     ISO Abbreviation:  Scand. J. Gastroenterol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0060105     Medline TA:  Scand J Gastroenterol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Departments of Surgical Gastroenterology, Neuroendocrine Tumour Centre of Excellence, Rigshospitalet , Copenhagen , Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Toe modifications in hind feet shoes optimise hoof-unrollment in sound Warmblood horses at trot.
Next Document:  Metabonomics of newborn screening dried blood spot samples - a novel approach in the screening and d...